Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer.

Prentice RL, Huang Y, Hinds DA, Peters U, Pettinger M, Cox DR, Beilharz E, Chlebowski RT, Rossouw JE, Caan B, Ballinger DG.

Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3079-85. doi: 10.1158/1055-9965.EPI-09-0611. Epub 2009 Oct 27.

2.

Breast cancer susceptibility associated with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a population-based United States study.

Andersen SW, Trentham-Dietz A, Figueroa JD, Titus LJ, Cai Q, Long J, Hampton JM, Egan KM, Newcomb PA.

Menopause. 2013 Mar;20(3):354-8. doi: 10.1097/GME.0b013e318268ca46.

3.

Variation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer.

Prentice RL, Huang Y, Hinds DA, Peters U, Cox DR, Beilharz E, Chlebowski RT, Rossouw JE, Caan B, Ballinger DG.

Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):74-9. doi: 10.1158/1055-9965.EPI-09-0663.

4.

FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: results of a case control study in Japan.

Kawase T, Matsuo K, Suzuki T, Hiraki A, Watanabe M, Iwata H, Tanaka H, Tajima K.

Int J Cancer. 2009 Oct 15;125(8):1946-52. doi: 10.1002/ijc.24505.

5.

Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen/progesterone receptor status.

Cen YL, Qi ML, Li HG, Su Y, Chen LJ, Lin Y, Chen WQ, Xie XM, Tang LY, Ren ZF.

Mol Carcinog. 2013 Nov;52 Suppl 1:E52-9. doi: 10.1002/mc.21979. Epub 2012 Nov 9.

PMID:
23143756
6.
7.

The association of polymorphisms in hormone metabolism pathway genes, menopausal hormone therapy, and breast cancer risk: a nested case-control study in the California Teachers Study cohort.

Lee E, Schumacher F, Lewinger JP, Neuhausen SL, Anton-Culver H, Horn-Ross PL, Henderson KD, Ziogas A, Van Den Berg D, Bernstein L, Ursin G.

Breast Cancer Res. 2011 Apr 1;13(2):R37. doi: 10.1186/bcr2859.

8.

Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.

MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk.

Breast Cancer Res Treat. 2010 Apr;120(3):727-36. doi: 10.1007/s10549-009-0489-8. Epub 2009 Aug 12.

PMID:
19672706
9.

Relation of FGFR2 genetic polymorphisms to the association between oral contraceptive use and the risk of breast cancer in Chinese women.

Xu WH, Shu XO, Long J, Lu W, Cai Q, Zheng Y, Xiang YB, Dai Q, Zhao GM, Gu K, Bao PP, Gao YT, Zheng W.

Am J Epidemiol. 2011 Apr 15;173(8):923-31. doi: 10.1093/aje/kwq460. Epub 2011 Mar 7.

10.

Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women.

Liang J, Chen P, Hu Z, Zhou X, Chen L, Li M, Wang Y, Tang J, Wang H, Shen H.

Carcinogenesis. 2008 Dec;29(12):2341-6. doi: 10.1093/carcin/bgn235. Epub 2008 Oct 8.

PMID:
18845558
11.

Functional analysis of a breast cancer-associated FGFR2 single nucleotide polymorphism using zinc finger mediated genome editing.

Robbez-Masson LJ, Bödör C, Jones JL, Hurst HC, Fitzgibbon J, Hart IR, Grose RP.

PLoS One. 2013 Nov 12;8(11):e78839. doi: 10.1371/journal.pone.0078839. eCollection 2013.

12.

Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.

Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC, Wactawski-Wende J, Chen C, Qi L, Yasmeen S, Newcomb PA, Prentice RL.

J Natl Cancer Inst. 2013 Apr 17;105(8):526-35. doi: 10.1093/jnci/djt043. Epub 2013 Mar 29.

13.

TNRC9 rs12443621 and FGFR2 rs2981582 polymorphisms and breast cancer risk.

Chen Y, Shi C, Guo Q.

World J Surg Oncol. 2016 Feb 24;14(1):50. doi: 10.1186/s12957-016-0795-7.

14.

Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium.

Campa D, Kaaks R, Le Marchand L, Haiman CA, Travis RC, Berg CD, Buring JE, Chanock SJ, Diver WR, Dostal L, Fournier A, Hankinson SE, Henderson BE, Hoover RN, Isaacs C, Johansson M, Kolonel LN, Kraft P, Lee IM, McCarty CA, Overvad K, Panico S, Peeters PH, Riboli E, Sanchez MJ, Schumacher FR, Skeie G, Stram DO, Thun MJ, Trichopoulos D, Zhang S, Ziegler RG, Hunter DJ, Lindström S, Canzian F.

J Natl Cancer Inst. 2011 Aug 17;103(16):1252-63. doi: 10.1093/jnci/djr265. Epub 2011 Jul 26.

15.

A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication.

Hein R, Flesch-Janys D, Dahmen N, Beckmann L, Lindström S, Schoof N, Czene K, Mittelstraß K, Illig T, Seibold P, Behrens S, Humphreys K, Li J, Liu J, Olson JE, Wang X, Hankinson SE, Truong T, Menegaux F, Dos Santos Silva I, Johnson N; GENICA Network, Chen ST, Yu JC, Ziogas A, Kataja V, Kosma VM, Mannermaa A, Anton-Culver H, Shen CY, Brauch H, Peto J, Guénel P, Kraft P, Couch FJ, Easton DF, Hall P, Chang-Claude J.

Breast Cancer Res Treat. 2013 Apr;138(2):529-542. doi: 10.1007/s10549-013-2443-z. Epub 2013 Feb 20.

16.

A study on genetic variants of Fibroblast growth factor receptor 2 (FGFR2) and the risk of breast cancer from North India.

Siddiqui S, Chattopadhyay S, Akhtar MS, Najm MZ, Deo SV, Shukla NK, Husain SA.

PLoS One. 2014 Oct 21;9(10):e110426. doi: 10.1371/journal.pone.0110426. eCollection 2014.

17.

Genetic variants of fibroblast growth factor receptor 2 (FGFR2) are associated with breast cancer risk in Chinese women of the Han nationality.

Chen F, Lu M, Xue Y, Zhou J, Hu F, Chen X, Zhao Z, Li Y, Wang X.

Immunogenetics. 2012 Jan;64(1):71-6. doi: 10.1007/s00251-011-0564-2. Epub 2011 Aug 6. Erratum in: Immunogenetics. 2013 Oct;65(10):763. Lv, Min [corrected to Lu, Min].

PMID:
21822685
18.

Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women.

Rebbeck TR, DeMichele A, Tran TV, Panossian S, Bunin GR, Troxel AB, Strom BL.

Carcinogenesis. 2009 Feb;30(2):269-74. doi: 10.1093/carcin/bgn247. Epub 2008 Nov 20.

19.

Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.

MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk.

Breast Cancer Res Treat. 2010 Jan;119(2):463-74. doi: 10.1007/s10549-009-0407-0. Epub 2009 May 8. Erratum in: Breast Cancer Res Treat. 2010 Jan;119(2):475.

PMID:
19424794
20.

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE.

N Engl J Med. 1995 Jun 15;332(24):1589-93.

Supplemental Content

Support Center